BLGOOTCChemicals & Allied ProductsFiscal year ends December 31
BIOLARGO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.07+0.00 (+0.90%)
Close on Oct 19, 2026
- Market cap
- $23.27M
- P/E (TTM)
- –
- Dividend yield
- –
Biolargo statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Chemicals & Allied Products companies for comparison
Valuation
| Measure | Biolargo | Industry median |
|---|---|---|
| Market Cap | $23.83M | $164.85M |
| Enterprise Value | $20.77M | $87.06M |
| PS Ratio | 5.84 | 3.60 |
Enterprise value
| Measure | Biolargo | Industry median |
|---|---|---|
| EV / Sales | 5.09 | 2.43 |
Income (trailing twelve months)
| Measure | Biolargo | Industry median |
|---|---|---|
| Revenue | $4.08M | $57.94M |
| Gross Profit | $1.63M | $90.47M |
| Operating Income | -$18.12M | -$21.44M |
| EBITDA | -$18.12M | -$16.91M |
| EPS (Diluted) | -$0.05 | -$0.83 |
Margins
| Measure | Biolargo | Industry median |
|---|---|---|
| Gross Margin | 40.0% | 52.3% |
| Operating Margin | -443.9% | -44.5% |
| EBITDA Margin | -443.9% | -31.3% |
Returns
| Measure | Biolargo | Industry median |
|---|---|---|
| Return on Invested Capital (ROIC) | -2157.8% | -32.0% |
| Return on Capital Employed (ROCE) | -951.8% | -37.8% |
Growth
| Measure | Biolargo | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -70.9% | 6.01% |
| Revenue Growth (3Y CAGR) | 9.69% | 2.25% |
| Revenue Growth (5Y CAGR) | 26.1% | 6.42% |
Balance sheet
| Measure | Biolargo | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.19M | $62.42M |
| Net Cash (Debt) | $2.19M | $15.68M |
| Net Cash Per Share | $0.01 | $0.66 |
| Equity (Book Value) | -$1.85M | $48.79M |
| Book Value Per Share | -$0.01 | $1.36 |
| Tangible Book Value | -$1.85M | $23.06M |
| Working Capital | -$1.27M | $75.77M |
Financial position
| Measure | Biolargo | Industry median |
|---|---|---|
| Current Ratio | 0.73 | 3.30 |
| Quick Ratio | 0.61 | 2.39 |
| Interest Coverage | -22.51 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Biolargo | Industry median |
|---|---|---|
| Operating Cash Flow | -$10.32M | -$12.35M |
Efficiency
| Measure | Biolargo | Industry median |
|---|---|---|
| Asset Turnover | 0.43 | 0.38 |
| Inventory Turnover | 6.56 | 2.67 |
| Revenue Per Employee | $88.76K | $398.96K |
| Employee Count | 46 | 74 |
Shares
| Measure | Biolargo | Industry median |
|---|---|---|
| Shares Outstanding | 328,731,000 | 58,179,650 |
| Shares Change (YoY) | 4.71% | 11.1% |
| Float | 257,608,000 | 49,173,100 |
| Shares Held by Insiders | 21.6% | 11.6% |
| Shares Held by Institutions | 0.04% | 59.4% |
Scores
| Measure | Biolargo | Industry median |
|---|---|---|
| Altman Z-Score | -41.98 | -0.24 |
Calculated by StockData from Biolargo's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.